SILVER SPRING, Md., August 28, 2026 — The U.S. Food and Drug Administration on Thursday approved Roivant Sciences’ (ROIV) oral JAK inhibitor brepocitinib, branded as Lisraya, for the treatment of adult dermatomyositis, marking the first oral therapy approved for the rare autoimmune disease. The approval, announced late Thursday, represents the first commercial launch for the hub-and-spoke pharma and could establish a multibillion-dollar franchise, according to analysts.

Lisraya offers an oral alternative to the injected standard of care. In the pivotal Phase 3 trial, the drug met its primary endpoint with a statistically significant improvement in Total Improvement Score (TIS) at 52 weeks. The oral convenience may broaden treatment uptake, though the drug will compete with established injectable therapies.

Source: Endpoints News (FDA approves Roivant’s Lisraya for dermatomyositis).

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

DUBLIN, Aug. 26, 2026 — Jazz Pharmaceuticals (JAZZ) and Zai Lab secured FDA approval late Monday for Ziihera (zanidatamab) in second-line HER2-positive gastroesophageal adenocarcinoma, according to a company statement cited by BioPharma Dive. The bispecific antibody, which targets two distinct HER2 epitopes, becomes the first FDA-approved HER2-directed therapy specifically indicated for this patient population after prior fluoropyrimidine- and platinum-based chemotherapy.

The approval triggers a $75 million milestone payment to Zai Lab under the 2022 regional licensing deal and positions Ziihera in a high-unmet-need indication where checkpoint inhibitors have shown limited single-agent activity. Jazz plans a U.S. commercial launch within two weeks.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON, Aug. 25, 2026 — A new industry snapshot from the Massachusetts Biotechnology Council (MassBio) shows a widening rift in venture funding for local biotechs. Median seed round sizes rose in the first half of 2026, while Series A rounds contracted, leaving the youngest, highest‑risk startups with fewer follow‑on dollars.

The report highlights that investors are concentrating larger checks in later‑stage, de‑risked companies. Meanwhile, firms with what MassBio terms “the riskiest science” face a widening funding gap between seed and Series A, a dynamic that could slow the progression of early discoveries into clinical programs.

The findings are detailed in MassBio’s mid‑year review, as reported by BioPharma Dive.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

Washington, Aug. 21, 2026 — More than four months into its search for a new CEO, the Pharmaceutical Research and Manufacturers of America (PhRMA) has considered Republican candidates including former lawmakers and Trump administration leaders, with decades of Capitol Hill experience and executive records, according to Endpoints News.

The trade group, which shapes industry positions on drug pricing, FDA policy, and intellectual property, is selecting its next leader as biopharma companies face implementation of Medicare drug price negotiations and continued scrutiny of launch prices.

Source: Endpoints News, “A mix of former Republican lawmakers and Trump admin leaders are in the race to lead PhRMA,” Aug. 20, 2026.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, August 20, 2026 — The White House has selected Heidi Overton as its nominee for FDA commissioner, according to STAT News. If confirmed, she would lead the agency at a time of active regulatory decisions across biotech and pharmaceutical pipelines.

The nomination carries immediate scrutiny. STAT News reported that Overton, a Trump loyalist, faces questions about potential competing interests from prior roles. Her confirmation process will test how the agency balances political alignment with regulatory independence.

Source: STAT News

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, Aug. 19, 2026 — A nonprofit physicians group that advocates for plant-based diets filed suit against the U.S. Department of Health and Human Services and the Department of Agriculture, alleging the agencies used a “secret panel” of scientists to revise the food pyramid, STAT News reports.

The challenge targets the process behind federal dietary guidance, a regulatory input that shapes clinical nutrition research, food and agriculture biotech priorities, and public health claims. A court ruling on advisory committee transparency could raise the evidentiary standard for how HHS and USDA convene scientific panels, with potential read-through for FDA advisory processes across the life sciences sector.

Source: STAT News, “Physician group sues Trump administration over dietary guidelines process,” August 19, 2026.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

SAN FRANCISCO, Aug 18, 2026 — Artificial intelligence systems will outperform physicians at certain basic medical tasks within the next five years, according to a report published Monday by Endpoints News. The finding, based on interviews with healthcare executives and venture capital investors, underscores the accelerating clinical capability of large language models and machine learning diagnostics. The prediction echoes recent advances in AI-driven radiology and pathology, where algorithms have matched or exceeded specialist accuracy in controlled settings, fueling investor interest in autonomous diagnostics. However, current FDA frameworks require clinician oversight for most AI-driven tools, a regulatory threshold that could be tested as autonomous performance improves.

Read the full analysis at Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEW YORK, Aug. 14, 2026 — Commure, which develops and sells AI products to clinics, has terminated a program that paid customers for referrals to new clients, according to STAT News.

The move removes a customer acquisition incentive tied to referrals for the company's clinical AI tools. It arrives as health systems face more pressure to evaluate vendor relationships and commercial compliance risks, particularly for AI software embedded in clinical workflows. Commure has not disclosed the size or duration of the referral program.

Source: STAT News, August 13, 2026.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEW YORK, Aug. 12, 2026 — Eli Lilly (NYSE: LLY) has paid $2 billion as the upfront consideration for its previously announced acquisitions of several vaccine-focused biotechnology companies, Endpoints News reported on Tuesday. The payment is part of a deal that could total up to $3.8 billion, signaling the pharmaceutical giant’s deepening commitment to next-generation vaccine platforms.

The move comes as large-cap pharma continues to diversify into RNA-based and other novel vaccine technologies, even as pandemic-era urgency wanes. Lilly’s upfront spend underscores the longer-term bet on vaccines as a durable growth category, separate from its dominant position in metabolic and neurodegenerative disease.

Full coverage, including separate financing rounds for Infinimmune ($75 million), Tenax Therapeutics, and others, is available from Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON, Aug 11, 2026 — Sionna Therapeutics (SION) disclosed that its lead cystic fibrosis candidate SION-109 failed to produce a statistically significant improvement in lung function when added to Vertex Pharmaceuticals’ (VRTX) Trikafta, upending analyst expectations. The Phase 2 combination trial, which enrolled patients already on the triple‑combination CFTR modulator, did not meet the primary endpoint of absolute change in ppFEV₁.

The result removes a near‑term competitive threat to Vertex’s dominant CF franchise, which generated $9.4 billion in Trikafta sales in 2025. Investors had positioned SION-109 as a potential supplementary therapy to enhance ion transport, but the study’s failure suggests the mechanism offers no incremental benefit over existing CFTR correction. Sionna shares fell 73% in premarket trading Monday.

According to BioPharma Dive, the outcome surprised analysts who had modeled a high probability of success based on earlier biomarker signals.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

Replimune (REPL) received FDA approval on Wednesday for tudriqev, an intratumoral oncolytic virus therapy for advanced melanoma, the company announced.

The green light is based on the Phase 3 IGNYTE trial, which reported a 45% overall response rate in patients with unresectable or metastatic melanoma who had progressed on PD-1 inhibitors. The approval marks a rebound for Replimune after the FDA issued a complete response letter in 2024, triggering a corporate restructuring.

Source: BioPharma Dive

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, August 6, 2026 — The FDA approved Moderna’s (MRNA) mRNA-based influenza vaccine late Wednesday, granting marketing authorization despite a recent public dispute between the company and former agency leaders over the accelerated approval pathway. The vaccine is the second mRNA product beyond COVID-19 cleared for Moderna, following its RSV vaccine, and arrives as the company publicly pivots its focus toward cancer therapies.

The approval underscores Moderna’s continued foothold in infectious disease, even as management emphasizes oncology pipeline expansion. The vaccine demonstrated non-inferior immunogenicity to a licensed comparator in Phase 3 studies, though the agency’s decision follows a months-long back-and-forth with ex-FDA officials who had questioned the use of accelerated approval for seasonal flu vaccines. Source: Endpoints News

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

FOSTER CITY, August 5, 2026 — Gilead Sciences (GILD) reported that its twice-yearly HIV prevention injection Yeztugo generated $232 million in second-quarter sales, exceeding the Wall Street consensus estimate of $221 million. The performance helped push the company’s total pre-exposure prophylaxis (PrEP) franchise above $1 billion in quarterly revenue for the first time, according to Endpoints News.

The beat, reported by Endpoints News, confirms robust commercial uptake for the long-acting injectable since its December 2025 FDA approval. Yeztugo’s second-quarter sales nearly doubled the $118 million recorded in the first quarter, signaling a rapid shift in PrEP prescribing patterns away from daily oral pills like Gilead’s own Descovy. With generic Descovy expected later this decade, the injectable franchise is central to Gilead’s long-term HIV portfolio strategy.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

The FDA on August 3 approved Novartis (NVS) radiopharmaceutical Pluvicto for use alongside standard hormone therapy in adults with metastatic castration-resistant prostate cancer, the agency and the company confirmed. The decision moves the targeted radioligand therapy into an earlier treatment setting, roughly doubling the eligible patient population according to Novartis.

Previously limited to patients who had already received chemotherapy and an androgen-receptor pathway inhibitor, Pluvicto can now be combined with a GnRH agonist and novel hormonal therapy. The label expansion reflects positive overall survival data from the phase 3 PSMAfore trial, which showed a statistically significant improvement compared to standard-of-care hormonal treatment alone. The move intensifies competition among advanced prostate cancer therapies and validates the growing role of radiopharmaceutical precision medicines.

Endpoints News first reported the expansion. Full details are available at Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEW BRUNSWICK, N.J., July 30, 2026 — Johnson & Johnson (JNJ) has agreed to pay $785 million upfront for an exclusive option to buy Sail Biomedicines, the in vivo CAR-T cell therapy company launched by Flagship Pioneering. The transaction values the potential acquisition at up to $2.58 billion if J&J exercises the option, marking one of the largest commitments to an in vivo cell engineering platform.

The deal allows J&J to extend its cell therapy franchise beyond its ex vivo CAR-T product Carvykti. Sail’s technology delivers genetic payloads directly into a patient’s body to reprogram T cells, bypassing the need for external cell harvesting and manufacturing. The move intensifies a race among large biopharma companies to secure next-generation, off-the-shelf cell therapies that could simplify supply chains and expand patient access.

The exclusive option agreement was first reported by Endpoints News on July 30.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

Johnson & Johnson (JNJ) proposed a $5.5 billion settlement late Monday to resolve tens of thousands of ovarian cancer claims tied to its talcum powder products, a move that could close a chapter of litigation stretching over a decade. The company’s three previous attempts to use subsidiary bankruptcies to manage the lawsuits failed, leaving the liability unresolved. The proposal, if accepted by claimants and courts, would remove a significant financial overhang that has pressured J&J’s consumer health division.

As reported by Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

OSLO, July 28, 2026 — International financing for the HIV response contracted 18% last year, a “profound shock” that risks reversing gains in the fight against the disease, according to a new UNAIDS report detailed by STAT News.

The decline comes as the Global Fund to Fight AIDS, Tuberculosis and Malaria faces a roughly $8 billion annual resource gap, and donor governments reallocate humanitarian budgets. UNAIDS estimates that without a rapid funding replenishment, the goal of ending AIDS as a public health threat by 2030 will be missed, with new HIV infections and AIDS-related deaths projected to rise in low- and middle-income countries.

Full report available via STAT News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

INDIANAPOLIS, July 23, 2026 — Eli Lilly (LLY) announced plans to file a marketing application with the U.S. Food and Drug Administration for its investigational obesity therapy retatrutide, a once‑weekly injectable that targets GIP, GLP‑1, and glucagon receptors.

The decision follows positive topline data from the Phase 3 program in adults with obesity or overweight with weight‑related comorbidities. Retatrutide would become the first triple‑hormone receptor agonist to reach the regulatory stage in the obesity market, potentially adding a new option beyond Lilly’s tirzepatide (Zepbound) and Novo Nordisk’s semaglutide (Wegovy).

Source: BioPharma Dive

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

OSLO, July 23, 2026 — Alex LeBrun, executive chairman of AI scribe company Nabla, detailed a concept known as a “world model” as a successor to large language models (LLMs) for clinical settings in an interview with STAT News on July 22.

The explanation arrives as the U.S. Food and Drug Administration continues to refine its oversight of artificial intelligence in medical devices, with draft guidance issued earlier this year stressing real-world performance monitoring and greater model transparency. LeBrun’s framing frames world models as capable of maintaining a persistent, structured representation of medical context — a feature that could address some of the reliability concerns regulators have flagged with traditional LLM-based note-taking and clinical decision support tools.

The full interview is available from STAT News’ AI Prognosis series.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, July 22, 2026 — A new Gallup survey released Wednesday reveals that 24% of U.S. workers are staying in jobs they would otherwise leave, solely to maintain their employer-sponsored health insurance coverage. The figure represents a sharp increase from prior years and signals deepening structural friction in the American labor market.

The phenomenon, termed job lock, has direct relevance to biotech investment analysis. Employer-sponsored insurance pools represent the primary reimbursement channel for most commercial therapeutics, from specialty biologics to gene therapies. Any sustained erosion in labor mobility — or a policy shock that decouples insurance from employment — would alter demand patterns, pricing leverage, and market access strategies across the sector. The survey arrives as several NIH-funded studies are examining how insurance design affects patient adherence to costly chronic-disease regimens.

Read the full survey findings at STAT News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEW YORK, July 21, 2026 — Tempus AI (NASDAQ: TEM) has reached a definitive agreement to acquire cancer test‑maker Personalis (NASDAQ: PSNL) in a transaction valued at $1.5 billion, the companies announced late Sunday. The deal adds Personalis’s next‑generation sequencing platform and molecular residual disease (MRD) assay to Tempus’s growing diagnostics portfolio.

The combination signals further consolidation in precision oncology as artificial intelligence‑enabled diagnostics firms seek to close the loop between genomic testing and therapeutic intelligence. Personalis brings a CLIA‑certified, FDA‑cleared laboratory and a pipeline of liquid biopsy products that complement Tempus’s data‑driven clinical decision support tools. The boards of both companies have unanimously approved the transaction, which is expected to close in the first half of 2027, subject to regulatory clearance and shareholder approvals.

Source: BioPharma Dive; company press releases.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

SAN DIEGO, July 17, 2026 — Mirador Therapeutics, a heavily funded immunology biotech, disclosed its first pipeline program on Thursday, striking a worldwide licensing deal for a drug from Kira Pharmaceuticals that targets the same complement 5a receptor as Amgen’s Tavneos (avacopan). The privately held San Diego company, which has raised over $650 million in venture capital, has been notably secretive about its research until now.

The agreement brings Mirador a clinical-stage asset designed to compete directly in the ANCA-associated vasculitis and other complement-mediated disease markets. Tavneos, originally from ChemoCentryx, was acquired by Amgen in 2022 and generated $421 million in 2025 sales. Mirador’s move signals a serious entry into the space, backed by substantial capital and a broad immunology pipeline still largely undisclosed. Endpoints News first reported the deal.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, July 16, 2026 — The death of U.S. Senator Lindsey Graham from an aortic dissection, reported Wednesday, has cast a spotlight on a rare vascular emergency that often presents without prior symptoms. According to a STAT News report, the condition occurs when the inner layer of the body's largest artery tears, allowing blood to split the vessel wall — a fatal event in many cases.

The disorder affects a small fraction of the population and has historically been difficult to predict, leaving a gap in both diagnostic and therapeutic development. While several medtech companies offer stent grafts for emergency repair, there remains no widely adopted screening tool for at‑risk patients. For the biotech sector, the high‑profile event may direct fresh investment attention toward biomarker‑based warning systems and genetic testing for connective‑tissue disorders linked to aortic fragility.

Primary source: STAT News, July 15, 2026.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

The Federal Trade Commission settled a lawsuit against CVS Health’s (CVS) pharmacy benefit manager, Caremark, on Tuesday, resolving charges that the company artificially inflated insulin prices and restricted patient access to the diabetes treatment, according to a report by STAT News. The settlement terms were not immediately disclosed, and CVS did not admit wrongdoing as part of the agreement.

The case marked one of the FTC’s most aggressive actions targeting the opaque rebate systems used by pharmacy benefit managers, which have been under bipartisan scrutiny for their role in driving up list prices for essential therapies. The settlement could pressure other major PBMs to restructure their formulary contracts, potentially reshaping the commercial landscape for insulin manufacturers.

Source: STAT News — FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access (July 14, 2026).

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

OSLO, July 14, 2026 — The U.S. Food and Drug Administration on July 13 released final clinical guidance for psychedelic drug developers and announced a planned public hearing on therapeutic use, providing regulatory clarity to a class approaching potential approvals. The document outlines trial design considerations for MDMA, psilocybin, and related compounds, addressing endpoint selection, safety monitoring, and the integration of psychotherapy in treatment protocols.

The guidance arrives as investor interest in psychedelic-assisted therapies intensifies, with several late-stage programmes targeting post-traumatic stress disorder and major depressive disorder. By scheduling a broader public hearing, the agency signals it is preparing to tackle the distinct regulatory challenges these modalities pose, well before new drug applications are submitted.

Source: Endpoints News — FDA finalizes guidance on psychedelics, plans broader hearing

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BASEL, July 10, 2026 — Roche (RHHBY) has discontinued development of tominersen, its antisense oligonucleotide for Huntington’s disease, after the Phase 2 GENERATION HD2 study showed no benefit over placebo. The company is also shelving an undisclosed early-stage Huntington’s asset, leaving no clinical-stage HD candidates in its pipeline.

The tominersen program spanned more than a decade and included a high-profile Phase 3 trial that was halted in 2021 due to a safety signal, followed by the redesigned Phase 2 study that now failed on efficacy. The withdrawal eliminates one of the few late-stage ASO approaches for HD, while Ionis Pharmaceuticals (IONS) continues early testing of an alternative allele-selective ASO.

The decision was first reported by Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

Health and Human Services Secretary Robert F. Kennedy Jr. announced on July 8 that the department will draft a new injury table for Covid‑19 vaccines under the Countermeasures Injury Compensation Program (CICP), STAT News reported. The table would list specific conditions presumed to be caused by the vaccines, shifting the burden of proof away from claimants seeking compensation.

Unlike the National Vaccine Injury Compensation Program, which uses a predefined injury table for routine childhood vaccines, the CICP currently lacks such a list for pandemic countermeasures. The move signals a potential structural change in how the government handles vaccine‑related injuries during public health emergencies, a topic that has drawn sharp political scrutiny since the rollout of Covid‑19 shots.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON, July 8, 2026 — Vertex Pharmaceuticals (VRTX) said it will acquire endocrinology startup Crinetics for $10 billion, marking the cystic fibrosis leader’s largest push beyond its core franchise. The deal, announced Tuesday, gives Vertex a pipeline of late-stage therapies for rare endocrine disorders.

The move signals Vertex’s ambition to diversify revenue as its CF franchise matures. Crinetics’ lead candidate, an oral ACTH antagonist, is in Phase 3 for Cushing’s disease, with additional programs in congenital adrenal hyperplasia. The deal mirrors large-cap biopharma’s appetite for targeted rare-disease assets with clear regulatory paths.

Reported by Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON — Vertex Pharmaceuticals (VRTX) will acquire San Diego-based Crinetics Pharmaceuticals (CRNX) for $10 billion in cash, the companies announced late Monday. The deal hands Vertex paltusotine, an oral somatostatin receptor agonist in Phase 3 development for acromegaly, a rare endocrine disorder caused by excess growth hormone.

Biopharma M&A remains brisk as large-cap firms deploy cash to fill pipelines facing looming patent cliffs. Paltusotine, if approved, would diversify Vertex beyond its cystic fibrosis franchise into endocrinology. The transaction is expected to close in the second half of 2026.

STAT News first reported the acquisition.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.